Pathologic fractures correlate with reduced survival in patients with malignant bone disease (Q80974012)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

Pathologic fractures correlate with reduced survival in patients with malignant bone disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

1 reference

1

Fred Saad

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Allan Lipton

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Richard Cook

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Yin-Miao Chen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Matthew Smith

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Robert Coleman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

1 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

1860-1867

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Strategies for management of prostate cancer-related bone pain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Estimating hip fracture morbidity, mortality and costs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

How many people develop fractures with what outcome?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Association between vertebral fracture and increased mortality in osteoporotic patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Incident vertebral fractures and mortality in older women: a prospective study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Controversies in the surgical management of skeletal metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Bisphosphonates in breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Clodronate in the prevention and treatment of skeletal metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22991

7 January 2021

Identifiers

DOI

10.1002/CNCR.22991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17763372%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference